Improvement in Liver Function Tests in a Male Patient with Primary Biliary Cholangitis Following Faecal Microbiota Transplantation (FMT): Case Report
This case report describes the first instance of faecal microbiota transplantation (FMT) in a male with primary biliary cholangitis, demonstrating that the procedure successfully restored gut microbial diversity and induced sustained improvements in liver function tests without the concurrent use of ursodeoxycholic acid.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The liver is a tireless worker, filtering blood and managing chemicals, but it can be attacked by its own immune system. In a condition called primary biliary cholangitis, the body mistakenly destroys the tiny tubes that carry bile, a digestive fluid, out of the liver. This blockage causes toxic substances to build up, leading to scarring, liver failure, and eventually death. While this disease strikes mostly women, it is becoming more common in men, who often face a more severe version of the illness. For decades, the standard treatment has been a daily medication that helps slow the damage, but for many patients, the disease continues to progress, leaving them with fatigue, itching, and a heavy reliance on pills.
Scientists have recently begun to suspect that the root of this problem might not be in the liver at all, but in the gut. The human intestine is home to trillions of microscopic organisms, a community known as the microbiome, which helps digest food and train the immune system. In patients with this liver disease, this internal ecosystem often becomes unbalanced, or "dysbiotic," with harmful bacteria taking over and beneficial ones disappearing. This imbalance may trigger the immune system to attack the liver. If the gut is the source of the trouble, then fixing the gut might fix the liver. This idea has led researchers to explore a procedure called fecal microbiota transplantation, where the healthy gut bacteria from a donor are transferred into a patient to restore balance.
A new case report details the first time this procedure was used on a man with primary biliary cholangitis. The patient, a 47-year-old man, had been living with the disease for years. Although he had no symptoms when first diagnosed, his liver function tests slowly worsened over time. He was started on the standard medication, which helped stabilize his condition, but he remained dependent on the drug. Seeking a way to reduce his reliance on lifelong medication, he agreed to undergo the bacterial transplant. Before the procedure, doctors collected a sample of his stool to analyze the specific types of bacteria living in his gut. They also collected samples from the healthy donor and a group of healthy people to use as a reference.
The transplant was performed by delivering the donor's processed stool directly into the patient's colon. Following the procedure, the patient's gut environment began to change in remarkable ways. Before the transplant, his gut bacteria were far less diverse than those of a healthy person, with a community structure that was skewed and unbalanced. After the transplant, the variety of bacteria in his gut increased significantly. His microbial profile began to look more like the donor's and more like the healthy reference group. Specifically, the number of different bacterial species he shared with the donor jumped from just 18 before the procedure to 110 afterward. This surge indicates that the donor's bacteria successfully took root and began to thrive in the patient's gut.
Crucially, the bacteria that moved in were the kind that help keep the gut healthy. Among the new arrivals were specific species known for producing compounds that reduce inflammation and protect the lining of the intestine. These beneficial bacteria were absent from the patient's gut before the transplant but became prominent afterward. At the same time, the patient's liver began to heal. His blood tests, which measure the stress and damage in the liver, showed a steady and sustained decline. Even as doctors gradually reduced his dosage of the standard medication, his liver enzymes continued to improve. Eight months after the transplant, one key marker of liver damage had returned to a normal range, while another continued to trend downward, though it remained slightly elevated.
The researchers observed that while the transplant successfully introduced new, healthy bacteria and improved the patient's liver function, it did not completely overwrite his entire gut ecosystem. Some of his original bacterial patterns remained, suggesting that the procedure partially restored balance rather than creating a perfect copy of the donor's gut. This finding is significant because it shows that even a partial shift toward a healthier microbial community can have a real, measurable impact on a serious liver disease. The study suggests that by targeting the gut, it may be possible to treat the liver, offering a potential path to reduce the need for daily medication and improve the quality of life for patients who struggle with this condition. While this is only a single case and further research is needed to confirm these results in larger groups, the outcome provides a promising glimpse into how fixing the gut might heal the liver.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.